Analysis of the association between immune-related adverse events and the effectiveness in patients with advanced non-small-cell-lung cancer
Patients with irAEs demonstrated better outcomes, including ORR, DCR, PFS, and OS. Further studies on biomarkers and irAE incidence are warranted to improve lung cancer management.
Authors
- Zhisheng Chen (ORCID: https://orcid.org/0000-0002-0854-2547)
- Haiyan Chen (ORCID: https://orcid.org/0009-0000-6926-6390)
- Jianying Liu (ORCID: https://orcid.org/0009-0006-2040-1188)
- Yijiao Xu (ORCID: https://orcid.org/0000-0002-4685-2378)
- Shuwen Yang (ORCID: https://orcid.org/0000-0002-3216-2376)
- Hongni Jiang
Institutions
- Xiamen University (CN)
- Fudan University (CN)
- First Affiliated Hospital of Xiamen University (CN)
- Zhongshan Hospital of Xiamen University (CN)
- Zhongshan Hospital (CN)
- Xiamen Blood Center (CN)
Publication Details
- Journal
- Discover Oncology
- Published
- 2024-10-08
- DOI
- https://doi.org/10.1007/s12672-024-01413-2
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.28
Funders
- Fudan University